Lixisenatide and beinaglutide Lixisenatide and beinaglutide, including EX-BID as discussed earlier, are classified as short-acting GLP-1RAs based on pharmacokinetic characteristics such as clearance half-life and concentration-time distribution
Weight loss does not always equal better healthand for many, these medications can pose nutritional, physical, and psychological challenges that arent worth the risk
Multidisciplinary approach for weight regainhow to manage this challenging condition: an expert review
Brand-name tirzepatide (sold as Mounjaro for diabetes or Zepbound for weight loss) costs $1,000-1,200/month at retail
However, both patients were able to use insulin glargine containing metacresol after exenatide allergy
Until those initiatives are fully implemented, we expect states to continue balancing coverage with immediate budget risks as cuts to federal Medicaid spending from H.R